<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940056</url>
  </required_header>
  <id_info>
    <org_study_id>UHOrebro</org_study_id>
    <nct_id>NCT00940056</nct_id>
    <nct_alias>NCT01047228</nct_alias>
  </id_info>
  <brief_title>Totally Endoscopic Ablation of Atrial Fibrillation</brief_title>
  <acronym>TEA</acronym>
  <official_title>Totally Endoscopic Ablation of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Örebro County</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective To evaluate the efficiency of totally endoscopic ablation of AF compared to
      rate control management of AF.

      Secondary Objectives

      Does totally endoscopic ablation:

        -  reduce atrial fibrillation symptoms?

        -  increase working capacity and improve quality of life?

        -  improve atrial function?

        -  reduce the risk for stroke?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized open controlled single centre study that involves 60 patients (men and
      women) over the age of 50 years with longstanding persistent AF of more than one year
      duration and in the absence of other severe cardiopulmonary disease. One of the participating
      investigators informs the patient, both verbally and in writing, about the study and what
      participation in the study involves. The patient will be given time to ask questions and to
      consider study participation and can be enrolled in the study after signing and dating
      written Informed Consent. Study duration per patient is 12 months.

      After inclusion, the patient will be divided into one of two groups, treatment group or
      control group, according to block wise randomization. The patient will be asked to complete
      two health related questionnaires SF 36 and SCL and a transthoracic echocardiography will be
      conducted together with an exercise test.

      The patients will thereafter be assessed according to randomisation. Irrespective of group,
      the patients will be rescheduled for a visit within two months for totally endoscopic
      ablation and Reveal implantation or just Reveal implantation (control group). All patients
      will then be assessed during follow-ups after 1, 3, 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom of AF 3 - 12 months postoperatively without antiarrhythmic drugs</measure>
    <time_frame>3-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom of symptomatic AF episodes 3 - 12 months</measure>
    <time_frame>3-12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity after 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life assessment (SF-36 and SCL) 3, 6 and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial function and dimensions after 6 and 12 months</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of thromboembolic events during the study</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Endoscopic ablation of atrial fibrillation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic ablation of AF</intervention_name>
    <description>The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .
After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care.</description>
    <arm_group_label>Endoscopic ablation of atrial fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rate control</intervention_name>
    <description>Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.</description>
    <arm_group_label>Rate control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 50 years

          2. Longstanding persistent AF of &gt; 1 year duration

          3. Severe symptoms related to AF

          4. Have signed and dated Informed Consent.

          5. Willing and able to comply with the protocol for the duration of the trial.

        Exclusion Criteria:

          1. Severe ischemic heart disease or heart valve disease

          2. Thrombus formation in left atrial appendage

          3. Intolerance to warfarin medication

          4. Advanced pulmonary disease, FEV 1 &lt; 1.5 litre

          5. Left atrial diameter &gt; 60 mm

          6. Body Mass Index (BMI) &gt; 35 kg/m2

          7. Previous pulmonary or heart surgery

          8. Participation in another clinical trial within the last 30 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Ahlsson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiothoracic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Espen Fengsrud, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders Englund, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Stockholm Arrhythmia Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Linde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Almroth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tommy Andersson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Tyden, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiothoracic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>70285</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J. 2006 Aug;27(16):1979-2030. Erratum in: Eur Heart J. 2007 Aug;28(16):2046.</citation>
    <PMID>16885201</PMID>
  </reference>
  <reference>
    <citation>European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Scoiety (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS), Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007 Jun;4(6):816-61. Epub 2007 Apr 30. Review. Erratum in: Heart Rhythm. 2009 Jan;6(1):148.</citation>
    <PMID>17556213</PMID>
  </reference>
  <reference>
    <citation>Matsutani N, Takase B, Ozeki Y, Maehara T, Lee R. Minimally invasive cardiothoracic surgery for atrial fibrillation: a combined Japan-US experience. Circ J. 2008 Mar;72(3):434-6.</citation>
    <PMID>18296841</PMID>
  </reference>
  <reference>
    <citation>Sagbas E, Akpinar B, Sanisoglu I, Caynak B, Tamtekin B, Oral K, Onan B. Video-assisted bilateral epicardial pulmonary vein isolation for the treatment of lone atrial fibrillation. Ann Thorac Surg. 2007 May;83(5):1724-30.</citation>
    <PMID>17462389</PMID>
  </reference>
  <reference>
    <citation>Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr, Gillinov AM. Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg. 2005 Sep;130(3):797-802. Erratum in: J Thorac Cardiovasc Surg. 2006 Apr;131(4):772.</citation>
    <PMID>16153931</PMID>
  </reference>
  <reference>
    <citation>La Meir M, De Roy L, Blommaert D, Buche M. Treatment of lone atrial fibrillation with a right thoracoscopic approach. Ann Thorac Surg. 2007 Jun;83(6):2244-5.</citation>
    <PMID>17532447</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Region Örebro County</investigator_affiliation>
    <investigator_full_name>Anders Ahlsson</investigator_full_name>
    <investigator_title>MD PHD</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Ablation</keyword>
  <keyword>Thoracoscopy</keyword>
  <keyword>Atrial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

